Back to discover
Disease

Developmental and epileptic encephalopathy, 13

Late-stage therapeutic development
Also known as DEE13, EIEE13, SCN8A early infantile epileptic encephalopathy, developmental and epileptic encephalopathy 13+6 more

DEE13, EIEE13, SCN8A early infantile epileptic encephalopathy, developmental and epileptic encephalopathy 13, early infantile epileptic encephalopathy caused by mutation in SCN8A, early infantile epileptic encephalopathy-13, epileptic encephalopathy, early infantile, 13, epileptic encephalopathy, early infantile, type 13, SCN8A encephalopathy, SCN8A epilepsy.

22
Clinical trials
5
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q1 2029.
Upcoming Milestones
Clinical Milestones13View all 13
Results posted 3
Results expected 4
Recently completed 5
Other updates 1
+5 more in the activity timeline below
Activity timeline13

Clinical trials

12 sponsors · 3 new · 6 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
22
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Phase 3 · Active, not recruiting · National Cancer Institute (NCI)

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Phase 3 · Active, not recruiting · ECOG-ACRIN Cancer Research Group

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Phase 2/3 · Active, not recruiting · National Cancer Institute (NCI)

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)

Phase 3 · Active, not recruiting · Children's Oncology Group
Recently completed

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Phase 3 · Completed · Shanghai Shengdi Pharmaceutical Co., Ltd

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)

Phase 3 · Completed · Shanghai Shengdi Pharmaceutical Co., Ltd

A Proof-of-concept Clinical Study to Evaluate the Impact of a Combination Nutraceutical Kit on Muscle Function, Cognitive Performance, and Immune Resilience in Older Adults.

Phase 4 · Completed · GPLIFE HEALTHCARE PRIVATE LIMITED

Biomarker-Driven Pharmacological Treatment for Autism Spectrum Disorder

Phase 4 · Completed · David Cochran

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Phase 3 · Completed · Children's Oncology Group

Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

Phase 3 · Completed · Children's Oncology Group

Associated genes

5 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SCN8A0.84ALDH7A10.33LYSMD20.12SCG30.12TMOD20.12

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Sodium channel protein type 8 subunit alphavia SCN8A0.84

Reference

Authoritative identity, definition & identifiers.

Synonyms

DEE13, EIEE13, SCN8A early infantile epileptic encephalopathy, developmental and epileptic encephalopathy 13, early infantile epileptic encephalopathy caused by mutation in SCN8A, early infantile epileptic encephalopathy-13, epileptic encephalopathy, early infantile, 13, epileptic encephalopathy, early infantile, type 13, SCN8A encephalopathy, SCN8A epilepsy

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.